Announcement on the Subsidiary's Receipt of the Decision of the Environmental Protection Department Ordering to Stop Production and Remediation
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2018-020
Bond Abbreviation: 13 Jianfeng 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement
of the Company's Board of Directors and all directors guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents
Recently, Anhui Xinbeika Chemical Co., Ltd. (hereinafter referred to as "Anhui Beika"), a subsidiary of the company, received the Dongzhi County Environmental Protection Bureau's "Decision on Ordering Suspension of Production and Rectification" (
Donghuan Zit [2018] No. 04), the main contents are hereby announced as follows:1. the contents of the "Decision on Ordering to Stop Production and Rectification"
(I) Investigation and Findings of Environmental Violations
After investigation by our bureau, it is found that your company has implemented the following environmental violations: "Your company's annual output of 500
tons of acetamiprid is in production, and the valve of the gas outlet pipeline of the activated carbon adsorption tank of the waste gas treatment facility in the 201 workshop is closed, the waste gas in the tank overflows from the outlet of the sewage pipe and the inlet and outlet of activated carbon replacement, etc., and the smell on site is heavy." The above facts ofare based on evidence such as the on-site (survey) record, investigation and inquiry record, on-site photos and so on on June 22, 2018
by our bureau.The above actions of your company violate the provisions of Article 20, paragraph 2, of the the People's Republic of China Air Pollution Prevention and Control Law.
The basis and type of the (II)'s decision to suspend production for rectification
According to Item (III) of Paragraph 1 of Article 99 of the the People's Republic of China Air Pollution Prevention and Control Law, and Item (I) of Article 6 of the Measures for the Implementation of Restrictions on Production and Suspension of Production by Environmental Protection Authorities, our bureau has decided to order your company to implement suspension of production for rectification.
Implementation method and deadline for (III) shutdown rectification
1
, your company shall immediately stop production from the date of receipt of this decision, and take corrective measures to formulate and implement the rectification plan.2
. Your company shall report the rectification plan to our bureau for the record and make it public within 15 working days after receiving this decision. The rectification plan shall determine the corrective measures, the progress of the project, the guarantee of funds and the responsible personnel.3
. After your company completes the rectification task, it shall report the completion of the rectification task and the public disclosure of the rectification information to our bureau for the record within 15 working days.4
. Your company shall not have any illegal pollutant discharge during the rectification period, and shall not resume production without reporting the completion of the rectification task to our bureau for the record.The period of suspension of production for rectification is from the date of service of this decision to the date of cancellation of the suspension of production for rectification.
Our bureau will supervise your unit after the implementation of the shutdown rectification, and conduct follow-up inspection after the shutdown rectification is lifted. If your company refuses to carry out rectification as required or commits illegal acts after resuming production, our bureau will impose administrative penalties or administrative treatment in accordance with the law according to your company's illegal circumstances and environmental consequences.
Ways and Time Limit for (IV) to Apply for Administrative Reconsideration or File Administrative Litigation
If your company does not accept this decision, it may apply for administrative reconsideration to Chizhou Municipal Environmental Protection Bureau or Dongzhi County People's Government within 60 days from the date of receipt of this decision in accordance with the provisions of Article 9 of the the People's Republic of China Administrative Reconsideration Law, an administrative lawsuit may also be brought to the people's Court of Dongzhi County within six months from the date of receipt of this decision in accordance with Article 46 of the the People's Republic of China Administrative procedure Law. If an application for administrative reconsideration or an administrative lawsuit is filed, the implementation of this decision shall not be suspended.
If you do not apply for administrative reconsideration, file an administrative lawsuit, or perform this decision within the time limit, our bureau will apply to the people's court for enforcement in accordance with the law.
2. Rectification Measures
Company attached great importance to the above decision and immediately requested Anhui Beika to actively cooperate with the environmental protection department in inspection and stop illegal acts. The specific measures are as follows:
1
. In response to the incident, the company instructed Jianfeng Pharmaceutical to immediately set up an environmental protection incident emergency working group to investigate the incident and supervise the rectification; at the same time, arrange the company's production enterprises to conduct a comprehensive environmental self-examination to prevent the occurrence of similar incidents.2
, prepare a rectification plan and arrange special funds to further upgrade the existing waste gas treatment system in Beika, Anhui Province.
3. During the period of shutdown and rectification, Anhui North Carolina will be arranged to carry out annual routine equipment maintenance to ensure the normal operation of production facilities after resumption of production.
Anhui North Carolina will complete the rectification as soon as possible and report the completion of the rectification to the Environmental Protection Bureau, so as to resume normal production as soon as possible.Impact of 3. on the Company
2018
In January and August, the board of directors of the company approved that the subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. acquired 55% of the equity of Shanghai Beika Pharmaceutical Technology Co., Ltd. by acquiring shares and increasing capital. Anhui Beika is a wholly-owned subsidiary of Shanghai Beika Pharmaceutical Technology Co., Ltd. In May 2018, the industrial and commercial change registration and handover procedures for the investment were completed. In accordance with the "Application Guide to Enterprise Accounting Standards No. 20-Business Combinations", the Company has included Shanghai Beika Pharmaceutical Technology Co., Ltd. and its subsidiaries in the scope of the Company's consolidation since June 2018.At the end of 2017
, the company's total assets were 41.76 .1 billion yuan, and the net assets attributable to the owners of the parent company were 2.627 billion yuan. In 2017, the company realized operating income of 2.827 billion yuan and realized net profit attributable to the owners of the parent company. 0.348 billion yuan. At the end of 2017, Anhui North Card's total assets were 0.047 billion yuan and net assets were 0.012 billion yuan. Anhui North Card's annual operating income in 2017 was 0.046 billion yuan and net profit was -0.008 billion yuan. Anhui North Card's total assets were about 1.13 of the company's total assets and its operating income was about 1.63 of the company's operating income. Anhui North Card has a small impact on the Company's overall operating income and efficiency.
The company will strictly follow the "Shanghai Stock Exchange Stock Listing Rules" and other relevant requirements to do a good job of information disclosure in a timely manner. Please invest rationally and pay attention to investment risks.This is to announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
July 5, 2018
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page